What is claimed is:

1. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

A, B, D, E, W, X, Y and Z are independently CR_1 or N;

T, U and V are independently CR_8 or N;

R_1 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L_a-R_a;

R_2 is selected from nitro, cyano, -NHOH, and groups of the formula L_a-R_a; with the proviso that R_2 is not hydrogen;

R_3 and R_4 are:

(a) each independently selected from (i) hydrogen and halogen; and (ii) C_1-C_8alkyl, C_2-C_8alkyl ether and -$(SO_2)C_1$-C_6alkyl, each of which is substituted with from 0 to 5 substituents independently chosen from halogen, hydroxy, amino, cyano and nitro; with the proviso that at least one of R_3 and R_4 is not hydrogen; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings; and dioxane, wherein each fused ring is substituted with from 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, C_1-C_6alkyl and C_1-C_6haloalkyl;

R_8 is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)amino, -$N(H)SO_2C_1$-C_6alkyl, -$N(SO_2C_1$-C_6alkyl$)_2$ and -$N(C_1$-C_6alkyl$)SO_2C_1$-C_6alkyl;

L_a is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, $S(O)_m$, $N(R_x)$, $N(R_x)C(=O)$, $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl; and

R_a is independently selected at each occurrence from:

(a) hydrogen; and

(b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), (5-membered heteroaryl)C_0-C_4alkyl and (5- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aminocarbonyl, aminoC_1-C_6alkyl, and mono- and di-(C_1-C_6alkyl)amino.

2. A compound or pharmaceutically acceptable form thereof according to claim 1, wherein A is N.

3. A compound or pharmaceutically acceptable form thereof according to claim 1 or claim 2, wherein R_2 is selected from cyano, nitro, NHOH, C_1-C_4alkyl, C_1-C_4haloalkyl, C_1-C_4hydroxyalkyl, C_1-C_4alkoxy, C_1-C_4alkylthio, C_1-C_4alkanoyl, aminoC_0-C_4alkyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), (C_5-C_6cycloalkyl)amino, (5- or 6-membered heterocycloalkyl)C_0-C_4alkyl, -N(R_x)SO_2C_1-C_4alkyl and -N(SO_2C_1-C_4alkyl)$_2$.

4. A compound or pharmaceutically acceptable form thereof according to claim 3, wherein R_2 is cyano, CHO, amino, nitro, methyl, ethyl, propyl, hydroxymethyl, trifluoromethyl, methoxy, ethoxy, propoxy, methylthio, ethylthio, (C_1-C_4alkyl)amino, (C_1-C_4alkyl)aminomethyl, cyclopentylamino, oxadiazolyl, -N(H)SO_2C_1-C_4alkyl, -N(CH_3)SO_2C_1-C_4alkyl or -N(SO_2CH_3)$_2$.

5. A compound or pharmaceutically acceptable form thereof according to claim 4, wherein R_2 is cyano, CHO, amino, nitro, methyl, trifluoromethyl, methoxy, ethoxy, propoxy, (C_1-C_4alkyl)amino, cyclopentylamino, -N(H)SO_2C_1-C_4alkyl, -N(CH_3)SO_2CH_3 or -N(SO_2CH_3)$_2$.

6. A compound or pharmaceutically acceptable form thereof according to any one of claims 1-5, wherein B and D are CR_1, and wherein each R_1 at B and D is independently selected from hydrogen, halogen, cyano, C_1-C_4alkyl, C_1-C_4haloalkyl and C_1-C_4alkoxy.

7. A compound or pharmaceutically acceptable form thereof according to any one of claims 1-6, wherein E is N or CR_1, wherein R_1 at E is hydrogen, C_1-C_4alkyl or C_1-C_2alkoxy.

8. A compound or pharmaceutically acceptable form thereof according to any one of claims 1-7, wherein W, Y and Z are CR_1, and wherein each R_1 at W, Y and Z is independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_4alkyl, C_1-

C_4haloalkyl, C_1-C_4alkoxy, -N(H)SO_2C_1-C_4alkyl, -N(C_1-C_4alkyl)SO_2C_1-C_4alkyl and -N(SO_2C_1-C_4alkyl)$_2$.

9. A compound or pharmaceutically acceptable form thereof according to claim 8, wherein X is N.

10. A compound or pharmaceutically acceptable form thereof according to claim 8, wherein each R_1 at W, Y and Z is independently chosen from hydrogen, halogen, hydroxy, amino, nitro and C_1-C_4alkyl.

11. A compound or pharmaceutically acceptable form thereof according to claim 8, wherein each R_1 at W, Y and Z is hydrogen.

12. A compound or pharmaceutically acceptable form thereof according to claim 10, wherein X is N or CH.

13. A compound or pharmaceutically acceptable form thereof according to any one of claims 1-12, wherein R_3 and R_4 are independently selected from hydrogen, halogen, C_1-C_4alkyl, C_2-C_4alkyl ether, C_1-C_4haloalkyl, C_1-C_4hydroxyalkyl and $-SO_2CF_3$; or wherein R_3 and R_4 are taken together to form a fused ring chosen from 5-membered carbocyclic and heterocyclic rings, phenyl, dioxane and dioxepane.

14. A compound or pharmaceutically acceptable form thereof according to claim 1, having the formula:



15. A compound or pharmaceutically acceptable form thereof according to claim 14, wherein:

A, T, U and X are independently N or CH;

D is CH;

each R_1 is independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_4alkyl, C_1-C_4haloalkyl, C_1-C_4alkoxy, -N(H)SO_2C_1-C_4alkyl, -N(C_1-C_4alkyl)SO_2C_1-C_4alkyl and -N(SO_2C_1-C_4alkyl)$_2$;

R_2 is cyano, CHO, amino, nitro, methyl, ethyl, propyl, trifluoromethyl, methoxy, ethoxy, propoxy, methylthio, ethylthio, -N(H)SO_2C_1-C_4alkyl, -N(CH_3)SO_2C_1-C_4alkyl or -N(SO_2CH_3)$_2$; and

R_3 and R_4 are independently selected from hydrogen, halogen, C_1-C_4alkyl, C_2-C_4alkyl ether, C_1-C_4haloalkyl, C_1-C_4hydroxyalkyl and $-SO_2CF_3$; or R_3 and R_4 are taken together to form a fused ring chosen from 5-membered carbocyclic and heterocyclic rings, phenyl, dioxane and dioxepane.

16. A compound or pharmaceutically acceptable form thereof according to claim 1, wherein the compound is:

2-Amino-N-(4-*tert*-butyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

2-Amino-N-(4-trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

2-Amino-N-(6-trifluoromethyl-pyridin-3-yl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

2-Hydroxy-N-(4-trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

2-Methanesulfonylamino-N-(4-trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

2-Nitro-N-(4-trifluoromethanesulfonyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

2-Nitro-N-(4-trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

3-Hydroxy-2'-trifluoromethyl-biphenyl-4-carboxylic acid (4-*tert*-butyl-phenyl)-amide;

4-(3-Amino-pyridin-2-yl)-N-(4-*tert*-butyl-phenyl)-benzamide;

4-(3-Amino-pyridin-4-yl)-N-(4-*tert*-butyl-phenyl)-benzamide;

4-(3-Nitro-pyridin-2-yl)-N-(4-trifluoromethyl-phenyl)-benzamide;

4-[3-(Butane-1-sulfonylamino)-pyridin-2-yl]-N-(4-*tert*-butyl-phenyl)-benzamide;

6-(2,4-Dimethoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;

6-(2,4-Dimethoxy-phenyl)-N-(4-propyl-phenyl)-nicotinamide;

6-(2,4-Dimethoxy-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;

6-(2,5-Dimethoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;

6-(2,5-Dimethoxy-phenyl)-N-(4-propyl-phenyl)-nicotinamide;

6-(2,5-Dimethyl-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;

6-(2,5-Dimethyl-phenyl)-N-(4-ethyl-phenyl)-nicotinamide;

6-(2,5-Dimethyl-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;

6-(2,5-Dimethyl-phenyl)-N-(4-propyl-phenyl)-nicotinamide;

6-(2,5-Dimethyl-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;

6-(2,5-Dimethyl-phenyl)-N-indan-5-yl-nicotinamide;

6-(2,6-Dimethoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;

6-(2,6-Dimethoxy-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;

6-(2-Acetyl-phenyl)-N-(4-*tert*-butyl-phenyl)-nicotinamide;

6-(2-Amino-phenyl)-N-(4-*tert*-butyl-phenyl)-nicotinamide;

6-(2-Methoxy-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;

6-(2-Methoxy-phenyl)-N-(4-propyl-phenyl)-nicotinamide;

6-(2-Methoxy-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;

6-(2-Methylsulfanyl-phenyl)-N-(4-propyl-phenyl)-nicotinamide;

6-(2-Methylsulfanyl-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(3,4-dimethyl-phenyl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(4-chloro-phenyl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(4-ethyl-phenyl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(4-propyl-phenyl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-indan-5-yl-nicotinamide;

6-(5-Fluoro-2-methoxy-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;

6-(5-Fluoro-2-methoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;

6-(5-Fluoro-2-methoxy-phenyl)-N-(4-propyl-phenyl)-nicotinamide;

6-(5-Fluoro-2-methoxy-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;

6-(5-Fluoro-2-methoxy-phenyl)-N-indan-5-yl-nicotinamide;

6-(5-Isopropyl-2-methoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;

6-Methyl-3'-trifluoromethyl-[2,2']bipyridinyl-5-carboxylic acid (4-trifluoromethyl-phenyl)-amide;

6-o-Tolyl-N-(2,3,4-trifluoro-phenyl)-nicotinamide;

6-o-Tolyl-N-(3-trifluoromethyl-phenyl)-nicotinamide;

6-o-Tolyl-N-(4-trifluoromethyl-phenyl)-nicotinamide;

6-o-Tolyl-N-p-tolyl-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(2,5-dimethoxy-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(2,5-dimethyl-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(2-methoxy-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-o-tolyl-nicotinamide;

N-(3,4-Dichloro-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;

N-(3,4-Dichloro-phenyl)-6-o-tolyl-nicotinamide;

N-(3,4-Difluoro-phenyl)-6-o-tolyl-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(2,5-dimethyl-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(2-methoxy-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-o-tolyl-nicotinamide;

N-(3,4-Dimethyl-phenyl)-6-(2,5-dimethyl-phenyl)-nicotinamide;

N-(3,4-Dimethyl-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;

N-(3,4-Dimethyl-phenyl)-6-(2-methylsulfanyl-phenyl)-nicotinamide;

N-(3,4-Dimethyl-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;

N-(3,4-Dimethyl-phenyl)-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;

N-(3,4-Dimethyl-phenyl)-6-o-tolyl-nicotinamide;

N-(3,5-Bis-trifluoromethyl-phenyl)-6-o-tolyl-nicotinamide;

N-(3,5-Dichloro-phenyl)-6-o-tolyl-nicotinamide;

N-(3-Chloro-phenyl)-6-o-tolyl-nicotinamide;

N-(3-Fluoro-4-methyl-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;

N-(3-Fluoro-4-methyl-phenyl)-6-(2-methylsulfanyl-phenyl)-nicotinamide;

N-(3-Fluoro-4-methyl-phenyl)-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;

N-(3-Fluoro-4-methyl-phenyl)-6-o-tolyl-nicotinamide;

N-(3-Fluoro-phenyl)-6-o-tolyl-nicotinamide;

N-(3-*tert*-Butyl-phenyl)-6-(2,5-dimethyl-phenyl)-nicotinamide;

N-(3-*tert*-Butyl-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;

N-(3-*tert*-Butyl-phenyl)-6-(2-methylsulfanyl-phenyl)-nicotinamide;

N-(3-*tert*-Butyl-phenyl)-6-(5-chloro-2-methoxy-phenyl)-nicotinamide;

N-(3-*tert*-Butyl-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;

N-(4-Bromo-2-fluoro-phenyl)-6-o-tolyl-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-(2,4-dimethoxy-phenyl)-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-(2,5-dimethoxy-phenyl)-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-(2,5-dimethyl-phenyl)-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-(2,6-dimethoxy-phenyl)-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-(2-methylsulfanyl-phenyl)-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-(5-chloro-2-methoxy-phenyl)-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-o-tolyl-nicotinamide;

N-(4-Bromo-3-trifluoromethyl-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;

N-(4-Butyl-phenyl)-6-(2,4-dimethoxy-phenyl)-nicotinamide;

N-(4-Butyl-phenyl)-6-(2,5-dimethyl-phenyl)-nicotinamide;

N-(4-Butyl-phenyl)-6-(2,6-dimethoxy-phenyl)-nicotinamide;

N-(4-Butyl-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;

N-(4-Butyl-phenyl)-6-(2-methylsulfanyl-phenyl)-nicotinamide;

N-(4-Butyl-phenyl)-6-(5-chloro-2-methoxy-phenyl)-nicotinamide;

N-(4-Butyl-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;

N-(4-Butyl-phenyl)-6-o-tolyl-nicotinamide;

N-(4-Chloro-phenyl)-6-(2,4-dimethoxy-phenyl)-nicotinamide;

N-(4-Chloro-phenyl)-6-(2,5-dimethyl-phenyl)-nicotinamide;

N-(4-Chloro-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;

N-(4-Chloro-phenyl)-6-(2-methylsulfanyl-phenyl)-nicotinamide;

N-(4-Chloro-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;

N-(4-Chloro-phenyl)-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;

N-(4-Chloro-phenyl)-6-o-tolyl-nicotinamide;

N-(4-Ethyl-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;

N-(4-Ethyl-phenyl)-6-(2-methylsulfanyl-phenyl)-nicotinamide;

N-(4-Ethyl-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;

N-(4-Ethyl-phenyl)-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;

N-(4-Ethyl-phenyl)-6-o-tolyl-nicotinamide;

N-(4-Fluoro-phenyl)-6-o-tolyl-nicotinamide;

N-(4-Isopropyl-phenyl)-6-(2-methoxy-phenyl)-nicotinamide;

N-(4-Isopropyl-phenyl)-6-(2-methylsulfanyl-phenyl)-nicotinamide;

N-(4-Isopropyl-phenyl)-6-o-tolyl-nicotinamide;

N-(4-Propyl-phenyl)-6-o-tolyl-nicotinamide;

N-(4-*tert*-Butyl-2-chloro-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;

N-(4-*tert*-Butyl-phenyl)-2-hydroxy-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-2-nitro-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-[1,3,4]oxadiazol-2-yl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-cyano-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-cyclopentylamino-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-dimethylaminomethyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-ethanesulfonylamino-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-formyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-hydroxyamino-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-hydroxymethyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-methanesulfonylamino-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-methyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-nitro-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-nitro-pyridin-4-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-propoxy-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-propylamino-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-pyrrolidin-1-ylmethyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-[3-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyridin-2-yl]-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-[3-(methanesulfonyl-methyl-amino)-pyridin-2-yl]-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-[3-(N,N-dimethanesulfonyl)amino-pyridin-2-yl]-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-[3-(N,N-dimethanesulfonyl)amino-pyridin-4-yl]-benzamide;

N-(4-*tert*-Butyl-phenyl)-6-(2,6-dimethyl-phenyl)-nicotinamide;

N-(4-*tert*-Butyl-phenyl)-6-(2-hydroxymethyl-phenyl)-nicotinamide;

N-(4-*tert*-Butyl-phenyl)-6-(2-methanesulfonylamino-phenyl)-nicotinamide;

N-(4-*tert*-Butyl-phenyl)-6-(2-nitro-phenyl)-nicotinamide;

N-(4-*tert*-Butyl-phenyl)-6-(2-trifluoromethyl-phenyl)-nicotinamide;

N-(4-*tert*-Butyl-phenyl)-6-[2-(N,N-dimethanesulfonyl)amino-phenyl]-nicotinamide;

N-(4-*tert*-Butyl-phenyl)-6-o-tolyl-nicotinamide;

N-(4-Trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

N-(4-Trifluoromethyl-phenyl)-4-[3-(N,N-dimethanesulfonyl)amino-pyridin-2-yl]-benzamide;

N-(5-Trifluoromethyl-pyridin-2-yl)-4-[3-(N,N-dimethanesulfonyl)amino-pyridin-2-yl]-benzamide;

N-Indan-5-yl-6-(2-methoxy-phenyl)-nicotinamide;

N-Indan-5-yl-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide; or

N-Indan-5-yl-6-o-tolyl-nicotinamide.

17. A compound of the formula:



wherein:

D, G, W, X, Y and Z are independently CR_1 or N;

T, U and V are independently CR_8 or N;

R_1 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

R_2 is halogen, cyano, nitro or a group of the formula L-M; with the proviso that R_2 is not hydrogen;

R_3 and R_4 are:

(a) independently chosen from R_8; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$ and -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl;

R_8 is independently chosen at each occurrence from:

(a) hydrogen, halogen, hydroxy, amino, cyano and nitro; and

(b) C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, -SO_2CF_3, 5- to 7-membered heterocycloalkyl, mono- and di-(C_1-C_6alkyl)amino, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$ and -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl; each of

which is substituted with from 0 to 3 substituents independently selected from hydroxy, halogen, cyano, oxo, C_1-C_4alkyl and C_1-C_4haloalkyl;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, $S(O)_m$, $N(R_x)$, $C(=O)N(R_x)$, $N(R_x)C(=O)$, $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), phenylC_0-C_4alkyl, (5-membered heteroaryl)C_0-C_4alkyl and (5- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aminocarbonyl, aminoC_1-C_6alkyl and mono- and di-(C_1-C_6alkyl)amino.

18. A compound or pharmaceutically acceptable form thereof according to claim 17, wherein R_3 is selected from:

(a) halogen; and

(b) C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, $-SO_2CF_3$, C_2-C_6alkyl ether and 5- to 7-membered heterocycloalkyl, each of which is substituted with from 0 to 3 substituents independently selected from hydroxy, halogen, cyano, oxo, C_1-C_4alkyl and C_1-C_4haloalkyl.

19. A compound or pharmaceutically acceptable form thereof according to claim 18, wherein R_3 is C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl or C_1-C_6cyanoalkyl.

20. A compound or pharmaceutically acceptable form thereof according to any one of claims 17-19, wherein W, Y and Z are CR_1, and wherein each R_1 at W, Y and Z is independently selected from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_4alkyl, C_1-C_4haloalkyl, C_1-C_4alkoxy,-$N(H)SO_2C_1$-C_4alkyl, -$N(C_1$-C_4alkyl)SO_2C_1-C_4alkyl and -$N(SO_2C_1$-C_4alkyl$)_2$.

21. A compound or pharmaceutically acceptable form thereof according to claim 20, wherein X is N.

22. A compound or pharmaceutically acceptable form thereof according to claim 20, wherein each R_1 at W, Y and Z is independently chosen from hydrogen, halogen, amino, hydroxy, nitro, C_1-C_4alkyl and $-NH(SO_2)CH_3$.

23. A compound or pharmaceutically acceptable form thereof according to claim 21, wherein each R_1 at W, Y and Z is hydrogen.

24. A compound or pharmaceutically acceptable form thereof according to claim 23, wherein X is N or CH.

25. A compound or pharmaceutically acceptable form thereof according to any one of claims 17-24, wherein R_2 is selected from:

(i) halogen, nitro, cyano and –NOH; and

(ii) C_1-C_6alkyl, C_1-C_6alkoxy, C_1-C_6alkylthio, C_1-C_6haloalkyl, C_1-C_6hydroxyalkyl, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, aminoC_0-C_6alkyl, mono- and di-(C_1-C_6alkyl)aminoC_0-C_6alkyl, oxadiazolyl, pyrazolyl, (5- or 6-membered heterocycloalkyl)C_0-C_6alkyl, -N(H)SO_2C_1-C_6alkyl, -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$ and -N(H)SO_2-(C_0-C_2alkyl)-phenyl; each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxy, cyano, C_1-C_4alkyl and C_1-C_4haloalkyl.

26. A compound or pharmaceutically acceptable form thereof according to claim 25, wherein R_2 is selected from fluoro, chloro, cyano, nitro, C_1-C_4alkyl, C_1-C_4haloalkyl, C_1-C_4hydroxyalkyl, C_1-C_4alkoxy, C_1-C_4alkylthio, C_1-C_4alkanoyl, aminoC_0-C_4alkyl, mono- and di-(C_1-C_4alkyl)aminoC_0-C_4alkyl, (C_5-C_6cycloalkyl)amino, (5- or 6-membered heterocycloalkyl)C_0-C_4alkyl, -N(H)SO_2C_1-C_4alkyl, -N(C_1-C_4alkyl)SO_2C_1-C_4alkyl and -N(SO_2C_1-C_4alkyl)$_2$.

27. A compound or pharmaceutically acceptable form thereof according to claim 26, wherein R_2 is cyano, CHO, amino, nitro, NHOH, methyl, ethyl, propyl, trifluoromethyl, methoxy, ethoxy, propoxy, methylthio, ethylthio, -N(H)SO_2C_1-C_4alkyl, -N(H)SO_2-phenyl, -N(CH_3)SO_2C_1-C_4alkyl or -N(SO_2CH_3)$_2$.

28. A compound or pharmaceutically acceptable form thereof according to claim 26, wherein R_2 is chloro, fluoro, cyano, nitro, amino, CHO, methyl, trifluoromethyl, C_1-C_4alkoxy, cyclopentylamino, pyrrolidin-1-ylmethyl, hydroxymethyl, oxadiazolyl, C_1-C_4alkylamino, dimethylaminomethyl, -N(CH_3)SO_2CH_3 or -N(SO_2CH_3)$_2$.

29. A compound or pharmaceutically acceptable form thereof according to claim 17, wherein the compound is:

2-Amino-N-(4-*tert*-butyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

2-Amino-N-(4-trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

2-Amino-N-(6-trifluoromethyl-pyridin-3-yl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

2-Hydroxy-N-(4-trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

2-Methanesulfonylamino-N-(4-trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

2-Nitro-N-(4-trifluoromethanesulfonyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

2-Nitro-N-(4-trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

2-Nitro-N-(6-trifluoromethyl-pyridin-3-yl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

4-(3-Amino-pyridin-2-yl)-N-(4-*tert*-butyl-phenyl)-benzamide;

4-(3-Benzenesulfonylamino-pyridin-2-yl)-N-(4-*tert*-butyl-phenyl)-benzamide;

4-(3-Chloro-pyridin-2-yl)-N-(4-isopropyl-3-methyl-phenyl)-benzamide;

4-(3-Chloro-pyridin-2-yl)-N-(4-isopropyl-phenyl)-benzamide;

4-(3-Chloro-pyridin-2-yl)-N-(5-trifluoromethyl-pyridin-2-yl)-benzamide;

4-(3-Chloro-pyridin-2-yl)-N-[4-(1-hydroxy-1-methyl-ethyl)-phenyl]-benzamide;

4-(3-Chloro-pyridin-2-yl)-N-[4-(2,2,2-trifluoro-1-methyl-ethyl)-phenyl]-benzamide;

4-(3-Chloro-pyridin-2-yl)-N-[4-(2-methoxy-1,1-dimethyl-ethyl)-phenyl]-benzamide;

4-(3-Chloro-pyridin-2-yl)-N-[4-(cyano-dimethyl-methyl)-phenyl]-benzamide;

4-(3-Fluoro-pyridin-2-yl)-N-(4-isopropyl-3-methyl-phenyl)-benzamide;

4-(3-Fluoro-pyridin-2-yl)-N-(4-isopropyl-phenyl)-benzamide;

4-(3-Fluoro-pyridin-2-yl)-N-(4-trifluoromethyl-phenyl)-benzamide;

4-(3-Nitro-pyridin-2-yl)-N-(4-trifluoromethyl-phenyl)-benzamide;

4-[3-(Butane-1-sulfonylamino)-pyridin-2-yl]-N-(4-*tert*-butyl-phenyl)-benzamide;

6-Methyl-3'-trifluoromethyl-[2,2']bipyridinyl-5-carboxylic acid (4-trifluoromethyl-phenyl)-amide;

N-(3,4-Difluoro-phenyl)-4-(3-fluoro-pyridin-2-yl)-benzamide;

N-(4-Butyl-phenyl)-4-(3-chloro-pyridin-2-yl)-benzamide;

N-(4-Cyclopentyl-phenyl)-4-(3-fluoro-pyridin-2-yl)-benzamide;

N-(4-Fluoro-phenyl)-4-(3-fluoro-pyridin-2-yl)-benzamide;

N-(4-sec-Butyl-phenyl)-4-(3-fluoro-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-2-hydroxy-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-2-nitro-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3,5-dichloro-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-[1,3,4]oxadiazol-2-yl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-chloro-pyrazin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-chloro-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-cyano-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-cyclopentylamino-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-dimethylaminomethyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-ethanesulfonylamino-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-fluoro-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-formyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-hydroxyamino-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-hydroxymethyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-methanesulfonylamino-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-methyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-nitro-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-phenylmethanesulfonylamino-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-propoxy-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-propylamino-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-pyrrolidin-1-ylmethyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-[3-(4-fluoro-benzenesulfonylamino)-pyridin-2-yl]-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-[3-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyridin-2-yl]-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-[3-(methanesulfonyl-methyl-amino)-pyridin-2-yl]-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-[3-(N,N-dimethanesulfonyl)amino-pyridin-2-yl]-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-[3-(toluene-4-sulfonylamino)-pyridin-2-yl]-benzamide;

N-(4-Trifluoromethyl-phenyl)-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide;

N-(4-Trifluoromethyl-phenyl)-4-[3-(N,N-dimethanesulfonyl)amino-pyridin-2-yl]-benzamide;

N-(5-Trifluoromethyl-pyridin-2-yl)-4-[3-(N,N-dimethanesulfonyl)amino-pyridin-2-yl]-benzamide; or

N-[4-(3-Ethyl-2,6-dioxo-piperidin-3-yl)-phenyl]-4-(3-fluoro-pyridin-2-yl)-benzamide.

30. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

A, B, E, D and G are independently CH, CR_7 or N; with the proviso that at least one of G, D and E is CR_7;

W, X, Y and Z are independently chosen from CR_1 and N;

T, U and V are independently chosen from CR_8 and N;

(R) represents a fused 5- or 7-membered carbocyclic or heterocyclic ring or a fused dioxane ring, wherein the fused ring is substituted with from 0 to 3 substituents independently selected from oxo, halogen, hydroxy, amino, cyano, nitro, C_1-C_4alkyl, C_1-C_4haloalkyl, C_1-C_4alkoxy and C_1-C_4haloalkoxy;

R_1 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

R_7 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M; with the proviso that R_7 is not hydrogen;

R_8 is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)amino, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$ and -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, $S(O)_m$, $N(R_x)$, $C(=O)N(R_x)$, $N(R_x)C(=O)$, $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl; and

M is independently selected at each occurrence from:

(a) hydrogen, and

(b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), phenylC_0-C_4alkyl, (5-membered heteroaryl)C_0-C_4alkyl and (5- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 5 substituents

independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aminocarbonyl, aminoC_1-C_6alkyl and mono- and di-(C_1-C_6alkyl)amino.

31. A compound or pharmaceutically acceptable form thereof according to claim 30, wherein at least two of W, X, Y and Z are CR_1, and at least one of T and U is CR_8.

32. A compound or pharmaceutically acceptable form thereof according to claim 30, wherein W, Y and Z are CR_1, and wherein each R_1 is independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_4alkyl, C_1-C_4haloalkyl, C_1-C_4alkoxy, -N(H)SO_2C_1-C_4alkyl, -N(C_1-C_4alkyl)SO_2C_1-C_4alkyl and -N(SO_2C_1-C_4alkyl)$_2$.

33. A compound or pharmaceutically acceptable form thereof according to claim 32, wherein each R_1 is independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_4alkyl, C_1-C_4haloalkyl and C_1-C_4alkoxy.

34. A compound or pharmaceutically acceptable form thereof according to claim 33, wherein each R_1 is hydrogen, and wherein X is N or CH.

35. A compound or pharmaceutically acceptable form thereof according to any one of claims 30-34, wherein X is N.

36. A compound or pharmaceutically acceptable form thereof according to any one of claims 30-35, wherein  is selected from cyclopentene, thiazole, dioxolane, dioxane and dioxepane, each of which is substituted with from 0 to 2 substituents independently selected from oxo, halogen, hydroxy, amino, cyano, nitro, C_1-C_4alkyl, C_1-C_4haloalkyl, C_1-C_4alkoxy, and C_1-C_4haloalkoxy.

37. A compound or pharmaceutically acceptable form thereof according to claim 36, wherein  is cyclopentene, cyclopentene substituted with oxo, thiazole or methylthiazole.

38. A compound or pharmaceutically acceptable form thereof according to claim 36, wherein  is dioxolane, dioxane or dioxepane.

39. A compound or pharmaceutically acceptable form thereof according to any one of claims 30-38, wherein G is CR_7.

40. A compound or pharmaceutically acceptable form thereof according to claim 39, wherein B, D and E are CH or CR_7.

41. A compound or pharmaceutically acceptable form thereof according to claim 39 or claim 40, wherein A is N or CH.

42. A compound or pharmaceutically acceptable form thereof according to claim 39, wherein R_7 at the G position is cyano, chloro, fluoro, nitro, C_1-C_4alkyl, C_1-C_4haloalkyl, C_1-C_4hydroxyalkyl, C_1-C_4alkoxy, C_1-C_4alkylthio, C_1-C_4alkanoyl, aminoC_0-C_4alkyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), (C_5-C_6cycloalkyl)amino, (5- or 6-membered heterocycloalkyl)C_0-C_4alkyl, -N(H)SO_2C_1-C_4alkyl, -N(H)SO_2-(C_0-C_2alkyl)-phenyl, -N(C_1-C_4alkyl)SO_2C_1-C_4alkyl or -N(SO_2C_1-C_4alkyl)$_2$.

43. A compound or pharmaceutically acceptable form thereof according to claim 30, wherein each R_7 is independently selected from halogen, amino, cyano, nitro, CHO, C_1-C_4alkyl, C_1-C_4haloalkyl, C_1-C_4alkoxy, C_1-C_4alkylthio, -N(H)SO_2C_1-C_4alkyl, -N(CH_3)SO_2C_1-C_4alkyl and -N(SO_2CH_3)$_2$.

44. A compound or pharmaceutically acceptable form thereof according to claim 30, wherein the compound is:

6-(2,4-Difluoro-phenyl)-N-indan-5-yl-nicotinamide;

6-(2,5-Dimethyl-phenyl)-N-indan-5-yl-nicotinamide;

6-(2-Chloro-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;

6-(2-Fluoro-phenyl)-N-(1-oxo-indan-5-yl)-nicotinamide;

6-(2-Fluoro-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;

6-(2-Fluoro-phenyl)-N-indan-5-yl-nicotinamide;

6-(2-Methoxy-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;

6-(3,4-Difluoro-phenyl)-N-indan-5-yl-nicotinamide;

6-(3,4-Dimethyl-phenyl)-N-indan-5-yl-nicotinamide;

6-(3-Chloro-phenyl)-N-indan-5-yl-nicotinamide;

6-(3-Ethoxy-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;

6-(3-Ethoxy-phenyl)-N-indan-5-yl-nicotinamide;

6-(3-Fluoro-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;

6-(3-Fluoro-phenyl)-N-indan-5-yl-nicotinamide;

6-(3-Isopropyl-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;

6-(3-Methoxy-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;

6-(4-Butyl-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;

6-(4-Chloro-phenyl)-N-indan-5-yl-nicotinamide;

6-(4-Fluoro-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;

6-(4-Fluoro-phenyl)-N-indan-5-yl-nicotinamide;

6-(4-Isopropyl-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-indan-5-yl-nicotinamide;

6-(5-Fluoro-2-methoxy-phenyl)-N-indan-5-yl-nicotinamide;

6-Biphenyl-3-yl-N-indan-5-yl-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(2,5-dimethoxy-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(2,5-dimethyl-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(2-fluoro-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(2-methoxy-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(3-ethoxy-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(3-fluoro-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(3-isopropyl-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(3-methoxy-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(4-isopropyl-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-m-tolyl-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-o-tolyl-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-p-tolyl-nicotinamide;

N-(2-Methyl-benzothiazol-5-yl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;

N-(2-Methyl-benzothiazol-5-yl)-6-m-tolyl-nicotinamide;

N-(2-Methyl-benzothiazol-5-yl)-6-p-tolyl-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(2,5-dimethyl-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(2-fluoro-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(2-methoxy-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(3-fluoro-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(3-isopropyl-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(3-methoxy-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(4-fluoro-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(4-isopropyl-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-m-tolyl-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-o-tolyl-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-p-tolyl-nicotinamide;

N-Indan-5-yl-6-(2-methoxy-phenyl)-nicotinamide;

N-Indan-5-yl-6-(3,4,5-trimethoxy-phenyl)-nicotinamide;

N-Indan-5-yl-6-(3-isopropyl-phenyl)-nicotinamide;

N-Indan-5-yl-6-(3-methoxy-phenyl)-nicotinamide;

N-Indan-5-yl-6-(3-trifluoromethoxy-phenyl)-nicotinamide;

N-Indan-5-yl-6-(3-trifluoromethyl-phenyl)-nicotinamide;

N-Indan-5-yl-6-(4-isopropyl-phenyl)-nicotinamide;

N-Indan-5-yl-6-(4-methoxy-phenyl)-nicotinamide;

N-Indan-5-yl-6-(5-isopropyl-2-methoxy-phenyl)-nicotinamide;

N-Indan-5-yl-6-m-tolyl-nicotinamide;

N-Indan-5-yl-6-o-tolyl-nicotinamide; or

N-Indan-5-yl-6-p-tolyl-nicotinamide.

45. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

J is N, NH, O or S;

A, B, E, D and G are independently CH, CR_7 or N; with the proviso that at least one of G, D and E is CR_7;

W, X, Y and Z are independently CR_1 or N;

T, U and V are independently CR_8 or N;

R_1 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-R_a;

R_7 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-R_a, with the proviso that R_7 is not hydrogen;

R_8 is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)amino, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$ and -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl;

R_9 represents from 0 to 2 substituents independently chosen from halogen, cyano, nitro, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_4haloalkyl, C_1-C_4haloalkoxy, mono- and di-(C_1-C_6alkyl)amino, and C_2-C_6alkyl ether;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, $S(O)_m$, $N(R_x)$, C(=O)$N(R_x)$, $N(R_x)C(=O)$, $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl; and

R_a is independently selected at each occurrence from:

(a) hydrogen; and

(b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), and (5- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aminocarbonyl, aminoC_1-C_6alkyl and mono- and di-(C_1-C_6alkyl)amino.

46. A compound or pharmaceutically acceptable form thereof according to claim 45, wherein at least two of W, X, Y and Z are CR_1, at least one of T and U is CR_8, and each R_1 and R_8 is independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_4alkyl, C_1-C_4haloalkyl and C_1-C_4alkoxy.

47. A compound or pharmaceutically acceptable form thereof according to claim 46, wherein W, Y and Z are CR_1, and wherein each R_1 is independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_4alkyl, C_1-C_4haloalkyl, C_1-C_4alkoxy, -N(H)SO_2C_1-C_4alkyl, -N(C_1-C_4alkyl)SO_2C_1-C_4alkyl and -N(SO_2C_1-C_4alkyl)$_2$.

48. A compound or pharmaceutically acceptable form thereof according to claim 47, wherein each R_1 is independently chosen from hydrogen, halogen, hydroxy and C_1-C_4alkyl.

49. A compound or pharmaceutically acceptable form thereof according to claim 48, wherein R_1 at W, Y and Z is hydrogen, and wherein X is N or CH.

50. A compound or pharmaceutically acceptable form thereof according to claim 46, wherein X is N.

51. A compound or pharmaceutically acceptable form thereof according to claim 45, wherein A is N or CH.

52. A compound or pharmaceutically acceptable form thereof according to claim 45, wherein G is CR_7.

53. A compound or pharmaceutically acceptable form thereof according to claim 52, wherein R_7 at the G position is cyano, chloro, fluoro, nitro, C_1-C_4alkyl, C_1-C_4haloalkyl, C_1-C_4hydroxyalkyl, C_1-C_4alkoxy, C_1-C_4alkylthio, C_1-C_4alkanoyl, aminoC_0-C_4alkyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), (C_5-C_6cycloalkyl)amino, (5- or 6-membered heterocycloalkyl)C_0-C_4alkyl, -N(H)SO_2C_1-C_4alkyl, -N(C_1-C_4alkyl)SO_2C_1-C_4alkyl or -N(SO_2C_1-C_4alkyl)$_2$.

54. A compound or pharmaceutically acceptable form thereof according to claim 45, wherein each R_7 is independently selected from halogen, amino, cyano, nitro, CHO, C_1-C_4alkyl, C_1-C_4haloalkyl, C_1-C_4alkoxy, C_1-C_4alkylthio, -N(H)SO_2C_1-C_4alkyl, -N(CH_3)SO_2C_1-C_4alkyl and -N(SO_2CH_3)$_2$.

55. A compound or pharmaceutically acceptable form thereof according to claim 45, wherein J is O.

56. A compound or pharmaceutically acceptable form thereof according to claim 45, wherein R_9 represents from 0 to 2 substituents independently chosen from halogen, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_4haloalkyl and C_1-C_4haloalkoxy.

57. A compound or pharmaceutically acceptable form thereof according to claim 45, wherein R_9 represents 0 substituents.

58. A compounds or form thereof according to claim 45, wherein:

J is O;

each R_7 is independently selected from halogen, amino, cyano, nitro, CHO, C_1-C_4alkyl, C_1-C_4haloalkyl, C_1-C_4alkoxy, C_1-C_4alkylthio, -N(H)SO_2C_1-C_4alkyl, -N(CH_3)SO_2C_1-C_4alkyl and -N(SO_2CH_3)$_2$;

R_1 at W, Y and Z is CR_1, wherein each R_1 is independently chosen from hydrogen, halogen, hydroxy and C_1-C_4alkyl;

A is N or CH; and

T and U are independently N or CH.

59. A compound or pharmaceutically acceptable form thereof according to claim 45, wherein the compound is:

6-(2,5-Dimethyl-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;

6-(2-Chloro-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;

6-(2-Fluoro-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;

6-(2-Methoxy-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;

6-(3,4-Dimethyl-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;

6-(3,5-Dimethyl-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;

6-(3-Isopropyl-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;

6-(4-Isopropyl-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;

6-(5-Isopropyl-2-methoxy-phenyl)-N-(4-morpholin-4-yl-phenyl)-nicotinamide;

N-(3-Chloro-4-morpholin-4-yl-phenyl)-6-(2-chloro-phenyl)-nicotinamide;

N-(3-Chloro-4-morpholin-4-yl-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;

N-(3-Chloro-4-morpholin-4-yl-phenyl)-6-o-tolyl-nicotinamide;

N-(4-Morpholin-4-yl-phenyl)-6-m-tolyl-nicotinamide; or

N-(4-Morpholin-4-yl-phenyl)-6-o-tolyl-nicotinamide.

60. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

A, T, W, X, Y, Z are independently CR_1 or N;

each R_1 and R_8 is independently chosen from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_4haloalkyl and C_1-C_4haloalkoxy;

either:

(a) R_2 is a halogen and R_5 is hydrogen; or

(b) R_2 is hydrogen and R_5 is a halogen; and

with regard to R_3 and R_4:

(a) R_3 is C_1-C_6alkyl and R_4 is hydrogen, halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_4haloalkyl or C_1-C_4haloalkoxy;

(b) R_3 is hydrogen, halogen, amino, cyano or C_1-C_4alkoxy; and R_4 is halogen, hydroxy, amino, cyano, C_1-C_4alkyl or C_1-C_4alkoxy; or

(c) R_3 and R_4 are taken together to form a 5- or 6-membered partially saturated carbocycle substituted with from 0 to 2 substituents independently chosen from halogen, hydroxy, amino, cyano, nitro, oxo, C_1-C_4alkyl and C_1-C_4alkoxy.

61. A compound or pharmaceutically acceptable form thereof according to claim 60, wherein:

W and X are CH;

A and T are independently CH or N;

Each R_8 is hydrogen; and

each R_1 is hydrogen or halogen.

62. A compound of form thereof according to claim 61, wherein R_3 is C_1-C_6alkyl and R_4 is hydrogen, methyl or halogen.

63. A compound or pharmaceutically acceptable form thereof according to claim 61, wherein R_3 is hydrogen or halogen and R_4 is halogen.

64. A compound or pharmaceutically acceptable form thereof according to claim 60, wherein the compound is:

2'-Chloro-biphenyl-4-carboxylic acid (4-*tert*-butyl-phenyl)-amide;

4-(3-Chloro-pyridin-2-yl)-N-(4-isopropyl-3-methyl-phenyl)-benzamide;

4-(3-Chloro-pyridin-2-yl)-N-(4-isopropyl-phenyl)-benzamide;

4-(3-Fluoro-pyridin-2-yl)-N-(4-isopropyl-3-methyl-phenyl)-benzamide;

4-(3-Fluoro-pyridin-2-yl)-N-(4-isopropyl-phenyl)-benzamide;

5-(2-Chloro-phenyl)-pyrazine-2-carboxylic acid (4-sec-butyl-phenyl)-amide;

5-(2-Chloro-phenyl)-pyrazine-2-carboxylic acid (4-*tert*-butyl-phenyl)-amide;

5-(2-Chloro-phenyl)-pyridine-2-carboxylic acid (4-*tert*-butyl-phenyl)-amide;

6-(2,4-Difluoro-phenyl)-N-(3,4-dimethyl-phenyl)-nicotinamide;

6-(2,4-Difluoro-phenyl)-N-indan-5-yl-nicotinamide;

6-(2-Chloro-phenyl)-N-(2,3,4-trifluoro-phenyl)-nicotinamide;

6-(2-Chloro-phenyl)-N-(3,4-dichloro-phenyl)-nicotinamide;

6-(2-Chloro-phenyl)-N-(3,4-difluoro-phenyl)-nicotinamide;

6-(2-Chloro-phenyl)-N-(3,5-dichloro-phenyl)-nicotinamide;

6-(2-Chloro-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;

6-(2-Chloro-phenyl)-N-(3-fluoro-phenyl)-nicotinamide;

6-(2-Chloro-phenyl)-N-(3-methoxy-phenyl)-nicotinamide;

6-(2-Chloro-phenyl)-N-(4-ethyl-phenyl)-nicotinamide;

6-(2-Chloro-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;

6-(2-Chloro-phenyl)-N-(4-propyl-phenyl)-nicotinamide;

6-(2-Chloro-phenyl)-N-m-tolyl-nicotinamide;

6-(2-Fluoro-phenyl)-N-(1-oxo-indan-5-yl)-nicotinamide;

6-(2-Fluoro-phenyl)-N-(3-methoxy-phenyl)-nicotinamide;

6-(2-Fluoro-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;

6-(2-Fluoro-phenyl)-N-(4-propyl-phenyl)-nicotinamide;

6-(2-Fluoro-phenyl)-N-indan-5-yl-nicotinamide;

6-(2-Fluoro-phenyl)-N-m-tolyl-nicotinamide;

6-(3,4-Difluoro-phenyl)-N-(3,4-dimethyl-phenyl)-nicotinamide;

6-(3,4-Difluoro-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;

6-(3,4-Difluoro-phenyl)-N-indan-5-yl-nicotinamide;

6-(3-Chloro-phenyl)-N-(3,4-dimethyl-phenyl)-nicotinamide;

6-(3-Chloro-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;

6-(3-Chloro-phenyl)-N-(4-ethyl-phenyl)-nicotinamide;

6-(3-Chloro-phenyl)-N-indan-5-yl-nicotinamide;

6-(3-Fluoro-phenyl)-N-(3-methoxy-phenyl)-nicotinamide;

6-(3-Fluoro-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;

6-(3-Fluoro-phenyl)-N-(4-propyl-phenyl)-nicotinamide;

6-(3-Fluoro-phenyl)-N-indan-5-yl-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(3,4-dimethyl-phenyl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(3-methoxy-phenyl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(4-ethyl-phenyl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-(4-propyl-phenyl)-nicotinamide;

6-(5-Chloro-2-methoxy-phenyl)-N-indan-5-yl-nicotinamide;

6-(5-Fluoro-2-methoxy-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;

6-(5-Fluoro-2-methoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;

6-(5-Fluoro-2-methoxy-phenyl)-N-(4-propyl-phenyl)-nicotinamide;

6-(5-Fluoro-2-methoxy-phenyl)-N-indan-5-yl-nicotinamide;

N-(3,4-Dichloro-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;

N-(3,4-Difluoro-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;

N-(3,4-Dimethoxy-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;

N-(3,4-Dimethyl-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;

N-(3,4-Dimethyl-phenyl)-6-(3-fluoro-phenyl)-nicotinamide;

N-(3,4-Dimethyl-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;

N-(3,5-Dichloro-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;

N-(3-Chloro-phenyl)-6-(2-chloro-phenyl)-nicotinamide;

N-(3-Chloro-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;

N-(3-Fluoro-4-methyl-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;

N-(3-Fluoro-4-methyl-phenyl)-6-(3-fluoro-phenyl)-nicotinamide;

N-(3-Fluoro-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;

N-(3-*tert*-Butyl-phenyl)-6-(2,4-difluoro-phenyl)-nicotinamide;

N-(3-*tert*-Butyl-phenyl)-6-(2-chloro-phenyl)-nicotinamide;

N-(3-*tert*-Butyl-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;

N-(3-*tert*-Butyl-phenyl)-6-(3,4-difluoro-phenyl)-nicotinamide;

N-(3-*tert*-Butyl-phenyl)-6-(3-chloro-phenyl)-nicotinamide;

N-(3-*tert*-Butyl-phenyl)-6-(3-fluoro-phenyl)-nicotinamide;

N-(3-*tert*-Butyl-phenyl)-6-(5-chloro-2-methoxy-phenyl)-nicotinamide;

N-(3-*tert*-Butyl-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-(2-chloro-phenyl)-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-(3-fluoro-phenyl)-nicotinamide;

N-(4-Butyl-phenyl)-4-(3-chloro-pyridin-2-yl)-benzamide;

N-(4-Butyl-phenyl)-6-(2-chloro-phenyl)-nicotinamide;

N-(4-Butyl-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;

N-(4-Butyl-phenyl)-6-(5-chloro-2-methoxy-phenyl)-nicotinamide;

N-(4-Butyl-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;

N-(4-Ethyl-phenyl)-6-(2-fluoro-phenyl)-nicotinamide;

N-(4-Ethyl-phenyl)-6-(3-fluoro-phenyl)-nicotinamide;

N-(4-Ethyl-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;

N-(4-sec-Butyl-phenyl)-4-(3-fluoro-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-2-chloro-phenyl)-6-(5-fluoro-2-methoxy-phenyl)-nicotinamide;

N-(4-*tert*-Butyl-phenyl)-4-(3,5-dichloro-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-chloro-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-4-(3-fluoro-pyridin-2-yl)-benzamide;

N-(4-*tert*-Butyl-phenyl)-5-chloro-6-(2-chloro-phenyl)-nicotinamide;

N-(4-*tert*-Butyl-phenyl)-6-(2,4-difluoro-phenyl)-nicotinamide;

N-(4-*tert*-Butyl-phenyl)-6-(2,6-difluoro-phenyl)-nicotinamide;

N-(4-*tert*-Butyl-phenyl)-6-(2-chloro-4-ethoxy-phenyl)-nicotinamide;

N-(4-*tert*-Butyl-phenyl)-6-(2-chloro-phenyl)-4-hydroxy-nicotinamide;

N-(4-*tert*-Butyl-phenyl)-6-(2-chloro-phenyl)-nicotinamide;

N-(4-*tert*-Butyl-phenyl)-6-(2-fluoro-phenyl)-nicotinamide; or

N-(4-*tert*-Butyl-phenyl)-6-(3-fluoro-phenyl)-nicotinamide.

65. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

A and T are independently CH or N;

W, X, Y and Z are independently CR_1 or N;

R_1 and R_8 are independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_4haloalkyl and C_1-C_4haloalkoxy;

R_3 and R_4 are:

(a) independently chosen from hydrogen, halogen, hydroxy, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_4haloalky and C_1-C_4haloalkoxy; or

(b) taken together to form a fused ring chosen from 5- to 7-membered partially saturated carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, wherein the fused ring is substituted with from 0 to 2 substituents independently chosen from halogen, hydroxy, amino, cyano, nitro, oxo, C_1-C_4alkyl, and C_1-C_4alkoxy;

R_5 is:

(a) C_1-C_6alkyl, C_1-C_6haloalkyl C_1-C_6alkenyl or C_1-C_6alkynyl; or

(b) taken together with R_6 to form a fused 5- to 7-membered partially saturated heterocycle; and

R_6 is:

(a) hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_4haloalkyl or C_1-C_4haloalkoxy; or

(b) taken together with R_5 to form a fused 5- to 7-membered partially saturated heterocycle.

66. A compound or pharmaceutically acceptable form thereof according to claim 65, wherein R_3 and R_4 are taken together to form a fused cyclopentene, thiazole, dioxolane or dioxane ring, each of which is unsubstituted or substituted with a methyl group.

67. A compound or pharmaceutically acceptable form thereof according to claim 65, wherein R_3 is C_1-C_6alkyl or halogen and R_4 is hydrogen, C_1-C_6alkyl or halogen.

68. A compound or pharmaceutically acceptable form thereof according to claim 65, wherein each R_1 and R_8 is hydrogen.

69. A compound or pharmaceutically acceptable form thereof according to claim 65, wherein the compound is:

6-(3,4-Dimethoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;

6-(3-Ethoxy-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;

6-(3-Ethoxy-phenyl)-N-(3-fluoro-4-methyl-phenyl)-nicotinamide;

6-(3-Ethoxy-phenyl)-N-(3-methoxy-phenyl)-nicotinamide;

6-(3-Ethoxy-phenyl)-N-(4-isopropyl-phenyl)-nicotinamide;

6-(3-Ethoxy-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;

6-(3-Ethoxy-phenyl)-N-indan-5-yl-nicotinamide;

6-(3-Methoxy-phenyl)-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;

6-(3-Methoxy-phenyl)-N-(4-propyl-phenyl)-nicotinamide;

6-(3-Trifluoromethoxy-phenyl)-N-(4-trifluoromethyl-phenyl)-nicotinamide;

6-Benzo[1,3]dioxol-5-yl-N-(2-methyl-benzothiazol-5-yl)-nicotinamide;

6-Benzo[1,3]dioxol-5-yl-N-(3,4-dimethyl-phenyl)-nicotinamide;

6-Benzo[1,3]dioxol-5-yl-N-(3-methoxy-phenyl)-nicotinamide;

6-Benzo[1,3]dioxol-5-yl-N-(3-*tert*-butyl-phenyl)-nicotinamide;

6-Benzo[1,3]dioxol-5-yl-N-(4-isopropyl-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(3-ethoxy-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(3-methoxy-phenyl)-nicotinamide;

N-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;

N-(2-Methyl-benzothiazol-5-yl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(3-methoxy-phenyl)-nicotinamide;

N-(3,4-Dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;

N-(3,4-Dimethyl-phenyl)-6-(3-ethoxy-phenyl)-nicotinamide;

N-(3,4-Dimethyl-phenyl)-6-(3-methoxy-phenyl)-nicotinamide;

N-(3,4-Dimethyl-phenyl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;

N-(3-Fluoro-4-methyl-phenyl)-6-(3-methoxy-phenyl)-nicotinamide;

N-(3-Methoxy-phenyl)-6-(3,4,5-trimethoxy-phenyl)-nicotinamide;

N-(3-Methoxy-phenyl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;

N-(3-*tert*-Butyl-phenyl)-6-(3,4,5-trimethoxy-phenyl)-nicotinamide;

N-(3-*tert*-Butyl-phenyl)-6-(3-methoxy-phenyl)-nicotinamide;

N-(3-*tert*-Butyl-phenyl)-6-(4-trifluoromethoxy-phenyl)-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-(3,4,5-trimethoxy-phenyl)-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-(3,4-dimethoxy-phenyl)-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-(3-ethoxy-phenyl)-nicotinamide;

N-(4-Bromo-3-chloro-phenyl)-6-(3-methoxy-phenyl)-nicotinamide;

N-(4-Butyl-phenyl)-6-(3-methoxy-phenyl)-nicotinamide;

N-(4-Chloro-phenyl)-6-(3-ethoxy-phenyl)-nicotinamide;

N-(4-Chloro-phenyl)-6-(3-methoxy-phenyl)-nicotinamide;

N-(4-Ethyl-phenyl)-6-(3,4,5-trimethoxy-phenyl)-nicotinamide;

N-(4-Ethyl-phenyl)-6-(3-methoxy-phenyl)-nicotinamide;

N-(4-Isopropyl-phenyl)-6-(3,4,5-trimethoxy-phenyl)-nicotinamide;

N-(4-Isopropyl-phenyl)-6-(3-trifluoromethoxy-phenyl)-nicotinamide;

N-(4-*tert*-Butyl-phenyl)-6-(3-methoxy-phenyl)-nicotinamide;

N-Indan-5-yl-6-(3,4,5-trimethoxy-phenyl)-nicotinamide;

N-Indan-5-yl-6-(3-methoxy-phenyl)-nicotinamide; or

N-Indan-5-yl-6-(3-trifluoromethoxy-phenyl)-nicotinamide.

70. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

T, U, V, W, X, Y and Z are independently CR_1 or N;

R_1 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

R_3 and R_4 are:

(a) independently chosen from R_1; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$ and -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl;

R_{20} is hydrogen, C_1-C_6alkyl, C_1-C_6alkanoyl or -SO_2C_1-C_6alkyl;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, $S(O)_m$, $N(R_x)$, C(=O)$N(R_x)$, $N(R_x)$C(=O), $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), phenylC_0-C_4alkyl and (5- to 7-membered heterocycle)C_0-C_4alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aminocarbonyl, aminoC_1-C_6alkyl and mono- and di-(C_1-C_6alkyl)amino.

71. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

A, B, E, D, G, W, X, Y and Z are independently CR_1 or N;

R_3 and R_4 are independently chosen from R_1;

R_1 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, $S(O)_m$, $N(R_x)$, C(=O)$N(R_x)$, $N(R_x)$C(=O), $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), phenylC_0-C_4alkyl and (5- to 7-membered heterocycle)C_0-C_4alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aminocarbonyl, aminoC_1-C_6alkyl and mono- and di-(C_1-C_6alkyl)amino.

72. A compound or pharmaceutically acceptable form thereof according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71, wherein the compound has an IC_{50} value of 100 nanomolar or less in a capsaicin receptor calcium mobilization assay.

73. A compound or pharmaceutically acceptable form thereof according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71, wherein the compound has an IC_{50} value of 10 nanomolar or less in a capsaicin receptor calcium mobilization assay.

74. A compound or pharmaceutically acceptable form thereof according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71, wherein the compound has an IC_{50} value of 1 nanomolar or less in a capsaicin receptor calcium mobilization assay.

75. A pharmaceutical composition, comprising at least one compound or pharmaceutically acceptable form thereof according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 in combination with a physiologically acceptable carrier or excipient.

76. A pharmaceutical composition according to claim 75, wherein the composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup or a transdermal patch.

77. A method for reducing calcium conductance of a cellular capsaicin receptor, comprising contacting a cell expressing a capsaicin receptor with at least one compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each ---- independently represents a single or double bond;

either: (a) A, B and E are independently CR_1, $C(R_1)_2$, NR_1 or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from R_1, and the other of A or E is CR_1, $C(R_1)_2$, NR_1 or N;

D and G are independently CR_1, $C(R_1)_2$, NR_1 or N;

W, X, Y and Z are independently CR_1 or N;

T, U and V are independently CR_8, $C(R_8)_2$, N or NH;

R_1 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

R_3 and R_4 are:

(a) independently chosen from R_8; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$, and -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl;

R_8 is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)amino, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$, -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, $S(O)_m$, $N(R_x)$, C(=O)$N(R_x)$, $N(R_x)$C(=O), $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), phenylC_0-C_4alkyl, (5-membered heteroaryl)C_0-C_4alkyl and (5- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aminocarbonyl, aminoC_1-C_6alkyl and mono- and di-(C_1-C_6alkyl)amino;

and thereby reducing calcium conductance of the capsaicin receptor.

78. A method according to claim 77, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.

79. A method according to claim 77, wherein the cell is a neuronal cell that is contacted *in vivo* in an animal.

80. A method according to claim 79, wherein during contact the compound is present within a body fluid of the animal.

81. A method according to claim 79, wherein the animal is a human.

82. A method according to claim 79, wherein the compound is administered orally.

83. A method for inhibiting binding of vanilloid ligand to a capsaicin receptor *in vitro*, the method comprising contacting capsaicin receptor with at least one compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each ---- independently represents a single or double bond;

either: (a) A, B and E are independently CR_1, $C(R_1)_2$, NR_1 or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from R_1, and the other of A or E is CR_1, $C(R_1)_2$, NR_1 or N;

D and G are independently CR_1, $C(R_1)_2$, NR_1 or N;

W, X, Y and Z are independently CR_1 or N;

T, U and V are independently CR_8, $C(R_8)_2$, N or NH;

R_1 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

R_3 and R_4 are:

(a) independently chosen from R_8; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$, and -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl;

R_8 is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)amino, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$, -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, $S(O)_m$, $N(R_x)$, C(=O)$N(R_x)$, $N(R_x)$C(=O), $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), phenylC_0-C_4alkyl, (5-membered heteroaryl)C_0-C_4alkyl and (5- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aminocarbonyl, aminoC_1-C_6alkyl and mono- and di-(C_1-C_6alkyl)amino;

under conditions and in an amount sufficient to detectably inhibit vanilloid ligand binding to capsaicin receptor.

84. A method according to claim 83, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.

85. A method for inhibiting binding of vanilloid ligand to capsaicin receptor in a patient, comprising contacting cells expressing capsaicin receptor in the patient with a compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each ---- independently represents a single or double bond;

either: (a) A, B and E are independently CR_1, $C(R_1)_2$, NR_1 or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from R_1, and the other of A or E is CR_1, $C(R_1)_2$, NR_1 or N;

D and G are independently CR_1, $C(R_1)_2$, NR_1 or N;

W, X, Y and Z are independently CR_1 or N;

T, U and V are independently CR_8, $C(R_8)_2$, N or NH;

R_1 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

R_3 and R_4 are:

(a) independently chosen from R_8; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$, and -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl;

R_8 is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)amino, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$, and -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, $S(O)_m$, $N(R_x)$, C(=O)$N(R_x)$, $N(R_x)$C(=O), $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), phenylC_0-C_4alkyl, (5-membered heteroaryl)C_0-C_4alkyl and (5- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aminocarbonyl, aminoC_1-C_6alkyl and mono- and di-(C_1-C_6alkyl)amino.

in an amount sufficient to detectably inhibit vanilloid ligand binding to cells expressing a cloned capsaicin receptor *in vitro*, and thereby inhibiting binding of vanilloid ligand to the capsaicin receptor in the patient.

86. A method according to claim 85, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.

87. A method according to claim 85, wherein the patient is a human.

88. A method for treating a condition responsive to capsaicin receptor modulation in a patient, comprising administering to the patient a capsaicin receptor modulatory amount of at least one compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each ---- independently represents a single or double bond;

either: (a) A, B and E are independently CR_1, $C(R_1)_2$, NR_1 or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from R_1, and the other of A or E is CR_1, $C(R_1)_2$, NR_1 or N;

D and G are independently CR_1, $C(R_1)_2$, NR_1 or N;

W, X, Y and Z are independently CR_1 or N;

T, U and V are independently CR_8, $C(R_8)_2$, N or NH;

R_1 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

R_3 and R_4 are:

(a) independently chosen from R_8; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-

C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$, and -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl;

R_8 is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)amino, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$, -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, $S(O)_m$, $N(R_x)$, C(=O)$N(R_x)$, $N(R_x)$C(=O), $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), phenylC_0-C_4alkyl, (5-membered heteroaryl)C_0-C_4alkyl and (5- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aminocarbonyl, aminoC_1-C_6alkyl and mono- and di-(C_1-C_6alkyl)amino.

and thereby alleviating the condition in the patient.

89. A method according to claim 88, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.

90. A method according to claim 88, wherein the patient is suffering from (i) exposure to capsaicin, (ii) burn or irritation due to exposure to heat, (iii) burns or irritation due to exposure to light, (iv) burn, bronchoconstriction or irritation due to exposure to tear gas, air pollutants or pepper spray, or (v) burn or irritation due to exposure to acid.

91. A method according to claim 88, wherein the condition is treating asthma or chronic obstructive pulmonary disease.

92. A method for treating pain in a patient, comprising administering to a patient suffering from pain a capsaicin receptor modulatory amount of at least one compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each ---- independently represents a single or double bond;

either: (a) A, B and E are independently CR_1, $C(R_1)_2$, NR_1 or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from R_1, and the other of A or E is CR_1, $C(R_1)_2$, NR_1 or N;

D and G are independently CR_1, $C(R_1)_2$, NR_1 or N;

W, X, Y and Z are independently CR_1 or N;

T, U and V are independently CR_8, $C(R_8)_2$, N or NH;

R_1 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

R_3 and R_4 are:

(a) independently chosen from R_8; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$, and -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl;

R_8 is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)amino, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$, -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, $S(O)_m$, $N(R_x)$, $C(=O)N(R_x)$, $N(R_x)C(=O)$, $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), phenylC_0-C_4alkyl, (5-membered heteroaryl)C_0-C_4alkyl and (5- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aminocarbonyl, aminoC_1-C_6alkyl and mono- and di-(C_1-C_6alkyl)amino.

and thereby alleviating pain in the patient.

93. A method according to claim 92, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.

94. A method according to claim 92, wherein the patient is suffering from neuropathic pain.

95. A method according to claim 92, wherein the patient is suffering from mechanical pain.

96. A method according to claim 92, wherein the pain is associated with a condition selected from: postmastectomy pain syndrome, stump pain, phantom limb pain, oral neuropathic pain, toothache, postherpetic neuralgia, diabetic neuropathy, reflex sympathetic dystrophy, trigeminal neuralgia, osteoarthritis, rheumatoid arthritis, fibromyalgia, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, bilateral peripheral neuropathy, causalgia, neuritis, neuronitis, neuralgia, AIDS-related neuropathy, MS-related neuropathy, spinal cord injury-related pain, surgery-related pain, musculoskeletal pain, back pain, headache, migraine, angina, labor, hemorrhoids, dyspepsia, Charcot's pains, intestinal gas, menstruation, cancer, venom exposure, irritable bowel syndrome, inflammatory bowel disease, and/or trauma.

97. A method according to claim 92, wherein the patient is a human.

98. A method for treating itch in a patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each ---- independently represents a single or double bond;

either: (a) A, B and E are independently CR_1, $C(R_1)_2$, NR_1 or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from R_1, and the other of A or E is CR_1, $C(R_1)_2$, NR_1 or N;

D and G are independently CR_1, $C(R_1)_2$, NR_1 or N;

W, X, Y and Z are independently CR_1 or N;

T, U and V are independently CR_8, $C(R_8)_2$, N or NH;

R_1 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

R_3 and R_4 are:

(a) independently chosen from R_8; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$, and -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl;

R_8 is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)amino, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$, -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, $S(O)_m$, $N(R_x)$, C(=O)$N(R_x)$, $N(R_x)$C(=O), $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and

$N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), phenylC_0-C_4alkyl, (5-membered heteroaryl)C_0-C_4alkyl and (5- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aminocarbonyl, aminoC_1-C_6alkyl and mono- and di-(C_1-C_6alkyl)amino.

and thereby alleviating itch in the patient.

99. A method according to claim 98, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.

100. A method for treating cough or hiccup in a patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each ---- independently represents a single or double bond;

either: (a) A, B and E are independently CR_1, $C(R_1)_2$, NR_1 or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from R_1, and the other of A or E is CR_1, $C(R_1)_2$, NR_1 or N;

D and G are independently CR_1, $C(R_1)_2$, NR_1 or N;

W, X, Y and Z are independently CR_1 or N;

T, U and V are independently CR_8, $C(R_8)_2$, N or NH;

R_1 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

R_3 and R_4 are:

(a) independently chosen from R_8; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$, and -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl;

R_8 is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)amino, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$ and -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, $S(O)_m$, $N(R_x)$, C(=O)$N(R_x)$, $N(R_x)$C(=O), $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), phenylC_0-C_4alkyl, (5-membered heteroaryl)C_0-C_4alkyl and (5- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aminocarbonyl, aminoC_1-C_6alkyl and mono- and di-(C_1-C_6alkyl)amino.

and thereby alleviating cough or hiccup in the patient.

101. A method according to claim 100, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.

102. A method for treating urinary incontinence in a patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each ---- independently represents a single or double bond;

either: (a) A, B and E are independently CR_1, $C(R_1)_2$, NR_1 or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from R_1, and the other of A or E is CR_1, $C(R_1)_2$, NR_1 or N;

D and G are independently CR_1, $C(R_1)_2$, NR_1 or N;

W, X, Y and Z are independently CR_1 or N;

T, U and V are independently CR_8, $C(R_8)_2$, N or NH;

R_1 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

R_3 and R_4 are:

(a) independently chosen from R_8; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$, and -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl;

R_8 is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)amino, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$,-N(C_1-C_6alkyl)SO_2C_1-C_6alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, $S(O)_m$, $N(R_x)$, C(=O)$N(R_x)$, $N(R_x)$C(=O), $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), phenylC_0-C_4alkyl, (5-membered heteroaryl)C_0-C_4alkyl and (5- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aminocarbonyl, aminoC_1-C_6alkyl and mono- and di-(C_1-C_6alkyl)amino;

and thereby alleviating urinary incontinence in the patient.

103. A method according to claim 102, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.

104. A method for promoting weight loss in an obese patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

each ---- independently represents a single or double bond;

either: (a) A, B and E are independently CR_1, $C(R_1)_2$, NR_1 or N; or

(b) B is joined with A or E to form a fused 5- to 8-membered partially saturated ring that is substituted with from 0 to 3 substituents independently selected from R_1, and the other of A or E is CR_1, $C(R_1)_2$, NR_1 or N;

D and G are independently CR_1, $C(R_1)_2$, NR_1 or N;

W, X, Y and Z are independently CR_1 or N;

T, U and V are independently CR_8, $C(R_8)_2$, N or NH;

R_1 is independently chosen at each occurrence from halogen, cyano, nitro and groups of the formula L-M;

R_3 and R_4 are:

(a) independently chosen from R_8; or

(b) taken together to form a fused ring selected from 5- to 8-membered carbocyclic rings, 5-membered heterocyclic rings, 7-membered heterocyclic rings and dioxane, each of which fused ring is substituted with from 0 to 3 substituents independently selected from halogen, hydroxy, amino, nitro, cyano, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-C_6alkyl ether, mono- and di-(C_1-C_6alkyl)aminoC_0-C_4alkyl, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$, and -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl;

R_8 is independently chosen at each occurrence from hydrogen, halogen, hydroxy, amino, cyano, nitro, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, C_1-C_6alkanoyl, C_2-

C_6alkyl ether, mono- and di-(C_1-C_6alkyl)amino, -N(H)SO_2C_1-C_6alkyl, -N(SO_2C_1-C_6alkyl)$_2$, -N(C_1-C_6alkyl)SO_2C_1-C_6alkyl, and 5 to 7 membered heteroalicyclic and heteroaryl rings;

L is independently chosen at each occurrence from a bond, O, C(=O), OC(=O), C(=O)O, O-C(=O)O, $S(O)_m$, $N(R_x)$, $C(=O)N(R_x)$, $N(R_x)C(=O)$, $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl; and

M is independently selected at each occurrence from (a) hydrogen; and (b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, mono- and di-(C_1-C_4alkyl)amino(C_0-C_4alkyl), phenylC_0-C_4alkyl, (5-membered heteroaryl)C_0-C_4alkyl and (5- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 5 substituents independently selected from halogen, hydroxy, cyano, nitro, amino, oxo, C_1-C_6alkyl, C_1-C_6haloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkoxy, aminocarbonyl, aminoC_1-C_6alkyl and mono- and di-(C_1-C_6alkyl)amino;

and thereby promoting weight loss in the patient.

105. A method according to claim 104, wherein the compound is a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71.

106. A compound or pharmaceutically acceptable form thereof according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71, wherein the compound or pharmaceutically acceptable form thereof is radiolabeled.

107. A method for determining the presence or absence of capsaicin receptor in a sample, comprising the steps of:

(a) contacting a sample with a compound or pharmaceutically acceptable form thereof according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 under conditions that permit binding of the compound to capsaicin receptor; and

(b) detecting a level of the compound bound to capsaicin receptor, and therefrom determining the presence or absence of capsaicin receptor in the sample.

108. A method according to claim 107, wherein the compound is a radiolabeled compound according to claim 106, and wherein the step of detection comprises the steps of:

(i) separating unbound compound from bound compound; and

(ii) detecting the presence or absence of bound compound in the sample.

109. A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim 75 in a container; and

(b) instructions for using the composition to treat pain.

110. A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim 75 in a container; and

(b) instructions for using the composition to treat cough or hiccup.

111. A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim 75 in a container; and

(b) instructions for using the composition to treat urinary incontinence.

112. A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim 75 in a container; and

(b) instructions for using the composition to treat obesity.

113. Use of a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 as a medicament for the treatment of a patient suffering from a condition responsive to capsaicin receptor modulation.

114. Use of a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 as a medicament for the treatment of a patient suffering from a condition responsive to capsaicin receptor modulation selected from (i) exposure to capsaicin, (ii) burn or irritation due to exposure to heat, (iii) burns or irritation due to exposure to light, (iv) burn, bronchoconstriction or irritation due to exposure to tear gas, air pollutants or pepper spray, or (v) burn or irritation due to exposure to acid.

115. Use of a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 as a medicament for the treatment of a patient suffering from to pain.

116. Use of a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 as a medicament for the treatment of a patient suffering from neuropathic pain associated with a condition selected from: postmastectomy pain syndrome, stump pain, phantom limb pain, oral neuropathic pain, toothache, postherpetic neuralgia, diabetic neuropathy, reflex sympathetic

dystrophy, trigeminal neuralgia, osteoarthritis, rheumatoid arthritis, fibromyalgia, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, bilateral peripheral neuropathy, causalgia, neuritis, neuronitis, neuralgia, AIDS-related neuropathy, MS-related neuropathy, spinal cord injury-related pain, surgery-related pain, musculoskeletal pain, back pain, headache, migraine, angina, labor, hemorrhoids, dyspepsia, Charcot's pains, intestinal gas, menstruation, cancer, venom exposure, irritable bowel syndrome, inflammatory bowel disease and trauma.

117. Use of a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 as a medicament for the treatment of a patient suffering from or susceptible to an itch.

118. Use of a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71as a medicament for the treatment of a patient suffering from or susceptible to urinary incontinence.

119. Use of a compound according to any one of claims 1, 17, 30, 45, 60, 65, 70 or 71 as a medicament for promoting weight loss in an obese patient.